RT Journal Article
SR Electronic
T1 CD206<sup>+</sup>IL-4Rα<sup>+</sup> MACROPHAGES ARE DRIVERS OF ADVERSE CARDIAC REMODELING IN ISCHEMIC CARDIOMYOPATHY
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.01.24314741
DO 10.1101/2024.10.01.24314741
A1 Wang, Qiongxin
A1 Ismahil, Mohamed Ameen
A1 Zhu, Yujie
A1 Rokosh, Gregg
A1 Hamid, Tariq
A1 Zhou, Guihua
A1 Pogwizd, Steven M.
A1 Prabhu, Sumanth D.
YR 2024
UL http://medrxiv.org/content/early/2024/10/03/2024.10.01.24314741.abstract
AB BACKGROUND Cardiac CD206+ macrophages expand acutely after myocardial infarction (MI) to promote wound healing; however, their role in chronic heart failure (HF) is unknown. We tested the hypothesis that cardiac CD206+ macrophages expressing interleukin(IL)-4Rα are key drivers of adverse left ventricular (LV) remodeling in HF.METHODS AND RESULTS Adult male C57BL/6 mice underwent non-reperfused MI to induce HF, or sham operation, and cardiac macrophages were profiled using flow cytometry. As compared to sham, CD206+ macrophages steadily expanded in post-MI hearts during LV remodeling, such that at 8 w post-MI they comprised ∼85% of all macrophages. These macrophages were robustly proliferative and predominantly C-C motif chemokine receptor (CCR2)- and major histocompatibility complex (MHC)IIhi, with &gt;90% of CD206+CCR2- macrophages expressing the resident macrophage marker LYVE-1. CD206+ macrophage abundance correlated with LV dysfunction and fibrosis. Nearly half of CD206+ macrophages expressed IL-4Rα, and the majority of CD206+IL-4Rα+ macrophages co-expressed the pro-fibrotic protein found in inflammatory zone (FIZZ)1. IL-4-polarized bone marrow derived CD206+ macrophages also exhibited marked upregulation of FIZZ1 and induced FIZZ1-dependent myofibroblast differentiation of cardiac mesenchymal stem cells (cMSCs), in part related to DLL-4/Jagged1-Notch1 signaling. Intramyocardial adoptive transfer of M[IL-4], but not M[IL-10], CD206+ macrophages to naïve mice, induced progressive LV remodeling over 4 weeks, increasing fibrosis, cardiomyocyte hypertrophy, and apoptosis. Myeloid-specific IL-4Rα gene deletion in established HF (initiated 4 w post-MI) in IL-4Rαf/fLysM-CreERT2 mice significantly reduced CD206+ macrophage proliferation and effectively depleted CD206+IL-4Rα+ cardiac macrophages. This was associated with abrogation of LV remodeling progression, reduction of cardiac fibrosis, and improved neovascularization. In vivo IL-4Rα gene silencing in mice with established HF effectively depleted cardiac CD206+IL-4Rα+ macrophages and reversed LV remodeling, improving fibrosis, neovascularization, and dysfunction, and suppressed both local and systemic inflammation. Lastly, alternatively activated CD206+ and CD163+ macrophages were significantly expanded in human failing hearts and correlated with fibrosis. The majority of CD163+ macrophages expressed IL-4Rα and FIZZ3, the human homolog of FIZZ1.CONCLUSION Cardiac CD206+IL-4Rα+ macrophages proliferate and expand in HF and are key mediators of pathological remodeling and fibrosis, in part through the secretion of FIZZ1. Inhibition of CD206+ macrophage IL-4Rα signaling alleviates LV remodeling in ischemic cardiomyopathy.What is new?In the failing heart after myocardial infarction (MI), CD206+ macrophages, primarily CCR2-, MHCIIhi, and LYVE1+, robustly proliferate with a subpopulation expressing IL-4Rα; myeloid-specific IL-4Rα deletion or IL-4Rα silencing in vivo tempered CD206+ macrophage proliferation and alleviated LV dysfunction, fibrosis, and remodeling.M[IL-4] CD206+ bone-marrow derived macrophages induced upregulation of Fizz1, and FIZZ1-dependent cardiac mesenchymal myofibroblast differentiation; intramyocardial adoptive transfer of M[IL-4] macrophages induced cardiac remodeling and fibrosis.Humans exhibit expansion of alternatively activated macrophages in the failing heart marked by CD206 and CD163 expression, with predominance of a subpopulation expressing IL-4Rα and Fizz3, the human homolog of Fizz1.What are the clinical implications?An expanded pool of alternatively activated CD206+IL-4Rα+ cardiac macrophages are key drivers of LV remodeling in heart failure, inducing an immuno-fibrotic and para-inflammatory response in part dependent on FIZZ1.Targeting IL-4 signaling in CD206+ macrophages represents a potential therapeutic approach to limit long-term cardiac remodeling in heart failure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Institutes of Health R01 HL157999 and HL147549 grants to SDP, and R01 HL137046 to TH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Alabama at Birmingham (UAB) Institutional Review Board (IRB) approved the human studies.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are available upon reasonable request.LVleft ventricularMImyocardial infarctionHFheart failureEFejection fractionEDVend-diastolic volumeESVend-systolic volumeLVADleft ventricular assist deviceBMDMbone marrow-derived macrophagecMSCcardiac mesenchymal stem cellASOantisense oligonucleotideCCR2C-C motif chemokine receptor 2ILinterleukinTGF-βtumor growth factor-βArg1arginase 1FIZZfound in inflammatory zoneColcollagenPDGFplatelet-derived growth factorα-SMAα-smooth muscle actinNICDNotch intracellular domain